Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...

The US Food and Drug Administration on Friday approved the first flu vaccine that does not have to be administered by a ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Investor Day. While these events are often catalysts for stock, ...

R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...